Clopidogrel
( DrugBank: Clopidogrel / KEGG DRUG: Clopidogrel bisulfate, Clopidogrel, Clopidogrel hydrochloride, Clopidogrel besilate )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 40 | Takayasu arteritis | 1 |
| 49 | Systemic lupus erythematosus | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 51 | Scleroderma | 2 |
| 86 | Pulmonary arterial hypertension | 1 |
40. Takayasu arteritis
Clinical trials : 30 / Drugs : 41 - (DrugBank : 22) / Drug target genes : 26 - Drug target pathways : 115
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
49. Systemic lupus erythematosus
Clinical trials : 1,227 / Drugs : 752 - (DrugBank : 175) / Drug target genes : 130 - Drug target pathways : 207
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
51. Scleroderma
Clinical trials : 639 / Drugs : 551 - (DrugBank : 157) / Drug target genes : 135 - Drug target pathways : 222
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
86. Pulmonary arterial hypertension
Clinical trials : 1,288 / Drugs : 565 - (DrugBank : 126) / Drug target genes : 81 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|